Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...
Zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback